Business, Policy & Funding
Breaking news on Precision Oncology business, policy & funding.
In Brief This Week: AstraZeneca, Merck, Stemline Therapeutics, Caris Life Sciences, Artios Pharma
News items for the week of Aug. 8, 2022.
AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer
The agency approved the first targeted therapy for this subset of non-small cell lung cancer patients based on data from the DESTINY-Lung02 trial.Â
Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations
The drug received accelerated approval two years earlier, but now the FDA is granting full approval based on confirmatory evidence of activity.Â
Clarified Precision Medicine, VieCure Partner to Make Precision Oncology Expertise More Accessible
VieCure will integrate Clarified's somatic and germline clinical consultation process within its AI platform, so oncologists have streamlined access to Clarified's precision oncology experts.
Roche Nabs FDA Label Expansion for Ventana CDx Panel
The immunohistochemistry companion diagnostic helps identify patients with solid tumors that are deficient in DNA mismatch repair.
Aug 5, 2022